Get Live Data

Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE
REMOVE ADS
REMOVE ADS

Latest Share Chat

  2. Share Prices
  3. Immupharma Share Price
  4. Immupharma Share Regulatory News
  5. Nominated Adviser Status

Pin to quick picksImmupharma Regulatory News (IMM)

Immupharma Information

Share Price Information for Immupharma (IMM)

Share Price is delayed by 15 minutes
Get Live Data
3.835    0.00 (0.00%)
Bid:
0.00
Ask:
0.00
Spread: 0.40 (10.54%)
Market Cap: £23.93m
IMM Live PriceLast checked at - London Stock Exchange

Intraday Immupharma Share Chart

Nominated Adviser Status

1 Nov 2018 13:38

RNS Number : 0704G
Immupharma PLC
01 November 2018
 

 

1 November 2018

 

 

 

ImmuPharma PLC

("ImmuPharma" or the "Company")

 

Nominated Adviser Status

 

ImmuPharma PLC (AIM: IMM.L), the specialist drug discovery and development company, announces that the Directors are aware of the proposed merger of its current nominated adviser ("NOMAD"), Northland Capital Partners ("Northland") with SP Angel Corporate Finance LLP. The Directors have also been informed that Northland has voluntarily agreed to relinquish its NOMAD status and will be removed from the register of NOMADs with effect from 7am (GMT) on 1 February 2019.

 

In accordance with AIM Rule 1, the Company is required to appoint a new NOMAD by 1 February 2019, if not, the Exchange will suspend trading in the Company's AIM Securities. If the Company does not appoint a replacement NOMAD by 4 March 2019, the admission of its AIM Securities will be cancelled.

 

The Company has commenced the process to appoint a new NOMAD and will make a further announcement in due course.

 

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 ("MAR").

 

 

For further information please contact:

 

ImmuPharma plc (www.immupharma.co.uk)

+ 44 (0) 20 7152 4080

Tim McCarthy, Chairman

Lisa Baderoon, Head of Investor Relations 

+ 44 (0) 7721 413496

 

Northland Capital Partners Limited (NOMAD & Joint Broker)David Hignell, Dugald Carlean, Jamie Spotswood, Corporate FinanceRob Rees, Corporate Broking

 

Stanford Capital Partners (Joint Broker)

Patrick Claridge

Chris Coleman

 

SI Capital (Joint Broker)

Nick Emerson

 

+44 (0)20 3861 6625

 

 

 

 

+44 (0) 20 3815 8880

 

 

+44 (0) 1483 413500

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
MSCUGGQWGUPRGWG
12345678910
Date   Source Headline
19th Aug 20214:35 pmRNSPrice Monitoring Extension
17th Aug 20218:50 amRNSNotification of Major Holdings
12th Aug 20217:00 amRNSFDA approves the Lupzuor™ PK study
10th Aug 20214:40 pmRNSSecond Price Monitoring Extn
10th Aug 20214:35 pmRNSPrice Monitoring Extension
30th Jul 20217:00 amRNSBoard Changes
16th Jul 20217:00 amRNSBoard Appointment
28th Jun 202112:27 pmRNS2021 RESULT OF ANNUAL GENERAL MEETING -REPLACEMENT
28th Jun 202111:03 amRNS2021 RESULT OF ANNUAL GENERAL MEETING
24th Jun 20214:41 pmRNSSecond Price Monitoring Extn
24th Jun 20214:36 pmRNSPrice Monitoring Extension
24th Jun 20217:00 amRNSUpdate: Lupzuor™ PK study
2nd Jun 20217:00 amRNSNotice of AGM and posting of Report & Accounts
24th May 20217:00 amRNSDirector Retirement
29th Apr 20214:35 pmRNSPrice Monitoring Extension
29th Apr 20217:00 amRNSFinal Results
16th Apr 20214:41 pmRNSSecond Price Monitoring Extn
16th Apr 20214:36 pmRNSPrice Monitoring Extension
25th Feb 20214:41 pmRNSSecond Price Monitoring Extn
25th Feb 20214:35 pmRNSPrice Monitoring Extension
9th Feb 20217:00 amRNSUpdate- scheduled Phase 3 trials in lupus patients
18th Jan 20217:00 amRNSAppointment of Company Secretary
4th Jan 20217:00 amRNSHolding(s) in Company
2nd Dec 20207:00 amRNSIMM TO PRESENT AT BIOTECH SHOWCASE DIGITAL 2021
30th Nov 20207:00 amRNSTotal Share Capital Notification
26th Nov 20207:00 amRNSGrant of Share Options & PDMR dealing
24th Nov 20207:00 amRNSConversion of Convertible Security
23rd Nov 20207:00 amRNSConversion of Convertible Security
20th Nov 20207:00 amRNSUpdate : FDA confirms 4 Dec for Type ‘A’ meeting
18th Nov 20207:00 amRNSTotal Share Capital Notification - Replacement
10th Nov 20207:00 amRNSUpdate on submission to the FDA
30th Sep 20207:01 amRNSTotal Share Capital Notification
30th Sep 20207:00 amRNSInterim Results
29th Sep 20207:00 amRNSShare Subscription into Incanthera plc
22nd Sep 20207:00 amRNSRepayment of Convertible Security
11th Sep 20207:59 amRNSUpdate on submission to the FDA
10th Sep 202010:59 amRNSConversion of Convertible Security
9th Sep 20201:45 pmRNSConversion of Convertible Security
8th Sep 20203:49 pmRNSHolding(s) in Company
8th Sep 20209:00 amRNSDirector/PDMR Shareholding / TR -1
7th Sep 20207:02 amRNSPlacing - update; related party transaction)
3rd Sep 20207:00 amRNSConversion of Convertible Security
2nd Sep 20207:00 amRNSPlacing to raise £6.5 million
1st Sep 20207:00 amRNSHolding(s) in Company
27th Jul 20207:00 amRNSFDA submission for Special Protocol Assessment
18th Jun 202011:31 amRNS2020 AGM – ALL RESOLUTIONS PASSED
16th Jun 20207:00 amRNSTotal Share Capital Notification
11th Jun 202012:00 pmRNSTR-1 Notification of major holdings
11th Jun 20207:00 amRNSSTRAT. INVTS FROM 2 SPECIALIST US H'CARE INVESTORS
5th Jun 20207:00 amRNSChange of Registered Office Address
12345678910

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Recently viewed
AMO
AMO.L
LSE
0.00%
CAU
Centaur
LSE
-16.15%
HGM
HGM.L
LSE
0.00%
MPAC
Mpac Group Plc
LSE
0.00%
BBIL
Jpm Ust 0-1 Etf
LSE
0.00%
Trending
GST
GSTechnologies
LSE
0.00%
GGP
Greatland Resources
LSE
0.00%
KEFI
Kefi Gold & Copper
LSE
0.00%
ALRT
Defence Holdings
LSE
0.00%
OMI
Orosur Mining
LSE
0.00%